Literature DB >> 11240257

Single-fraction irradiation has no effect on uptake of radiolabeled pegylated liposomes in a tumor xenograft model.

K J Harrington1, G Rowlinson-Busza, P S Uster, R G Vile, A M Peters, J S Stewart.   

Abstract

PURPOSE: These studies were performed with the intention of examining the effect of single-fraction doses of radiotherapy (RT) on the tumor deposition of radiolabeled pegylated liposomes in an animal xenograft tumor model. METHODS AND MATERIALS: Human KB head-and-neck xenograft tumors were established in female nude mice. The effect of single fraction tumor RT doses (5, 10, 15, and 20 Gy) on the tumor uptake of intravenously administered (111)In-DTPA-labeled pegylated liposomes (IDLPL) was examined using two protocols: (1) to test the effect of RT delivered 30 min before liposome injection on the time course of tumor uptake over a 96-h period; (2) to test the effect of RT at times ranging from 72-h to 1-h before liposome injection on the levels of liposome uptake at 24 h. Tumor and normal tissue/organ (blood, liver, spleen, lung, and kidney) liposome uptake was determined by dissection and quantitation in a gamma counter.
RESULTS: There was no demonstrable effect of RT on tumor uptake of IDLPL (p > 0.1 for all comparisons). Reassuringly, neither was there an effect of RT on the pharmacokinetics and biodistribution of radiolabeled liposomes to normal tissues.
CONCLUSIONS: Single fraction doses of RT appear to have no effect on tumor or normal tissue biodistribution and pharmacokinetics of radiolabeled pegylated liposomes in this animal model.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11240257     DOI: 10.1016/s0360-3016(00)01444-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  6 in total

Review 1.  Integrating nanomedicine into clinical radiotherapy regimens.

Authors:  Allison N DuRoss; Megan J Neufeld; Shushan Rana; Charles R Thomas; Conroy Sun
Journal:  Adv Drug Deliv Rev       Date:  2019-07-04       Impact factor: 15.470

2.  Micellar Formulation of Talazoparib and Buparlisib for Enhanced DNA Damage in Breast Cancer Chemoradiotherapy.

Authors:  Allison N DuRoss; Megan J Neufeld; Madeleine R Landry; Justin G Rosch; Colin T Eaton; Gaurav Sahay; Charles R Thomas; Conroy Sun
Journal:  ACS Appl Mater Interfaces       Date:  2019-03-21       Impact factor: 9.229

3.  Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment.

Authors:  Oliver K Appelbe; Qingbei Zhang; Charles A Pelizzari; Ralph R Weichselbaum; Stephen J Kron
Journal:  Mol Pharm       Date:  2016-09-01       Impact factor: 4.939

4.  Gamma-irradiated liposome/noisome and lipogelosome/niogelosome formulations for the treatment of rheumatoid arthritis.

Authors:  Selcan Turker; A Yekta Ozer; Ekrem Kiliç; Meral Ozalp; Seyda Colak; Mustafa Korkmaz
Journal:  Interv Med Appl Sci       Date:  2013-07-04

5.  Liposomal doxorubicin improves radiotherapy response in hypoxic prostate cancer xenografts.

Authors:  Eirik Hagtvet; Kathrine Røe; Dag R Olsen
Journal:  Radiat Oncol       Date:  2011-10-07       Impact factor: 3.481

Review 6.  Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.

Authors:  M I Koukourakis; K Romanidis; M Froudarakis; G Kyrgias; G V Koukourakis; G Retalis; N Bahlitzanakis
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.